case_images: PMC8187800_01
case_images: CT after chemotherapy indicated tumor progression. Left: CT of September 20, 2018. Bladder cancer with retroperitoneal and pelvic lymph node metastasis. Right: CT of November 12, 2018. After two cycles of gemcitabine chemotherapy, retroperitoneal and pelvic lesions progressed.
case_images: fonc-11-646322-g001.jpg
case_images: PMC8187800_01_fonc-11-646322-g001.jpg
case_images: f1
case_images: After two cycles of gemcitabine treatment, the patient's disease continued to progress ( Figure 1 ). Serum creatinine level slightly decreased at first, then increased markedly ( Figure S1 ).
case_images: CT after nivolumab indicated tumor response. Compare CT of April 18, 2019 (B) with February 20, 2019 (A) Bladder cancer with liver, abdominal cavity, retroperitoneal, pelvic, bilateral inguinal lymph node metastasis, part of the liver lesions and lymph nodes shrink. CT of June 3, 2019 (C) and March 2, 2021 (D) showed no lesions were found in the liver, abdominal cavity, retroperitoneal, pelvic.
case_images: fonc-11-646322-g002.jpg
case_images: PMC8187800_01_fonc-11-646322-g002.jpg
case_images: f2
case_images: CT scan demonstrated a partial response to immunotherapy ( Figures 2A, B ), and an increase in the kidney graft volume ( Figures 3A, B ). Figure 2C ) and further swelling of the transplanted kidney. Four months after the third course (August, 2019), CT scan indicated a persistent complete response, and the swelling transplanted kidney was smaller than previous. No recurrence was observed ( Figure 2D ).
case_images: CT scan of the volume of transplanted kidney. Compare CT of April 18, 2019 (B) with February 20, 2019. (A) The volume of transplanted kidney increased after treatment of nivolumab. Compare CT of March 2, 2021 (C) with April 18, 2019. (B) The volume of transplanted kidney decreased after nivolumab stopped.
case_images: fonc-11-646322-g003.jpg
case_images: PMC8187800_01_fonc-11-646322-g003.jpg
case_images: f3
case_images: CT scan demonstrated a partial response to immunotherapy ( Figures 2A, B ), and an increase in the kidney graft volume ( Figures 3A, B ). Regular CT scan was carried out every three months. 23 months after the third course (March, 2021), CT confirmed a further decrease in swelling of the transplanted kidney and restoration of the kidney to its former volume ( Figure 3C ).